SCHEDULE 13D/A: Major Shareholder Anebulo Pharmaceuticals Increases Stake to 51.1% and Enters Key Governance Agreements

Anebulo Pharmaceuticals, Inc. announces that Aron R. English and affiliated entities now beneficially own 51.1% of its common stock, following a private placement and new lock-up and support agreements.

Summary

• Aron R. English, 22NW Fund, LP, and Pharma Investors, LLC (collectively, the 'Reporting Persons') beneficially own an aggregate of 21,929,880 shares of Anebulo Pharmaceuticals, Inc. common stock, representing 51.1% of the outstanding shares.
• This beneficial ownership includes 104,475 shares from options exercisable within 60 days for Aron English and 1,703,577 shares from warrants exercisable within 60 days held by 22NW Fund, LP.
• The percentage is calculated based on 41,084,731 shares of Common Stock outstanding as of December 23, 2024.
• 22NW Fund, LP holds 17,170,877 shares (40.1%) and Pharma Investors, LLC holds 4,654,528 shares (11.3%).
• On December 22, 2024, Anebulo Pharmaceuticals, Inc. entered into a private placement, issuing 15,151,514 shares of Common Stock to investors, with 10,101,010 shares issued to 22NW Fund, LP at $0.99 per share. The private placement closed on December 23, 2024.
• On February 24, 2025, the Company and 22NW Fund, LP entered into a Lock-Up Agreement, restricting 22NW from voting, selling, transferring, pledging, or otherwise disposing of the 10,101,010 shares acquired in the private placement.
• The Company committed to holding a stockholder meeting no later than April 30, 2025, to submit a proposal for the removal of these voting and transfer restrictions.
• Failure to hold the meeting or remove the restrictions by April 30, 2025, would constitute a breach of the Lock-Up Agreement, granting 22NW the right to have the shares redeemed.
• An Irrevocable Instruction Letter was issued to the Company's transfer agent to enforce the lock-up and legend the shares.
• On February 24, 2025, the Reporting Persons and Dr. Joseph Lawler entered into a Support Agreement, where the Reporting Persons agreed to vote their beneficially owned shares in favor of Dr. Lawler's election to the board of directors at the 2025 Annual Meeting and all subsequent meetings.
• Also on February 24, 2025, Dr. Joseph Lawler entered into a separate Support Agreement, agreeing to vote his shares in favor of the proposal to remove the lock-up restrictions at the 2025 Annual Meeting and in favor of Aron English's election to the board at subsequent meetings.

Sentiment

Score: 7

Explanation: The filing indicates a significant shareholder increasing their stake and formalizing governance agreements, which can be seen as a positive for stability and alignment. However, the lock-up agreement introduces a temporary restriction on a large block of shares, and the breach clause adds a minor risk. Overall, it suggests a committed major shareholder.

Positives

• The private placement provided capital to Anebulo Pharmaceuticals, Inc. by issuing 15,151,514 shares at $0.99 per share.
• The formalization of voting agreements between major shareholders and directors (Aron English, 22NW Fund, Pharma Investors, and Dr. Joseph Lawler) indicates increased alignment and potential stability in corporate governance.
• The commitment from Dr. Lawler to support the removal of lock-up restrictions could eventually enhance liquidity for 22NW Fund, LP's significant shareholding.

Negatives

• The Lock-Up Agreement temporarily restricts 22NW Fund, LP from voting, selling, transferring, or pledging 10,101,010 shares, potentially limiting liquidity for a significant portion of their holdings until stockholder approval is obtained.
• The agreement includes a provision for redemption rights for 22NW if the Company fails to meet the deadline or secure stockholder approval for removing the lock-up restrictions, introducing a potential future obligation for the Company.

Risks

• Risk of breach of the Lock-Up Agreement if Anebulo Pharmaceuticals, Inc. fails to hold the 2025 Annual Meeting by April 30, 2025, or fails to secure stockholder approval for the removal of voting and transfer restrictions, which would grant 22NW Fund, LP redemption rights for the locked-up shares.
• The voting agreements, while formalizing support, could be perceived as entrenching current board members (Dr. Lawler and Aron English), potentially limiting future shareholder influence on board composition.

Future Outlook

Anebulo Pharmaceuticals, Inc. is obligated to hold a stockholder meeting by April 30, 2025, to vote on removing the voting and transfer restrictions on shares held by 22NW Fund, LP. Additionally, future meetings will include votes on the election of Dr. Joseph Lawler and Aron English to the board, with formal support from the Reporting Persons and Dr. Lawler, respectively.

Industry Context

This filing primarily details changes in significant ownership and corporate governance within Anebulo Pharmaceuticals, Inc. It does not provide information to analyze broader industry trends or competitive positioning, focusing instead on internal corporate control dynamics.

Management Changes

Corporate Governance

Related Party Transactions

• Anebulo Pharmaceuticals, Inc. issued 10,101,010 shares of Common Stock to 22NW Fund, LP in a private placement on December 23, 2024. 22NW Fund, LP is a greater than 5% stockholder of the Company and is controlled by Aron English, a director of the Company.

Stakeholder Impact

• Shareholders: The lock-up agreement temporarily restricts the voting and transferability of a significant block of shares held by a major investor, which could affect market dynamics. The support agreements formalize voting intentions for director elections, potentially influencing future board composition and stability. The private placement diluted existing shareholders but provided capital to the company.
• Management/Board: The support agreements ensure the re-election of Dr. Joseph Lawler and Aron English, providing stability to the board's composition.

Next Steps

• Anebulo Pharmaceuticals, Inc. to hold a stockholder meeting no later than April 30, 2025.
• Company to submit a proposal at the 2025 Annual Meeting to remove voting and transfer restrictions on shares held by 22NW Fund, LP.
• Reporting Persons to vote their shares in favor of Dr. Joseph Lawler's election to the board at the 2025 Annual Meeting and subsequent meetings.
• Dr. Joseph Lawler to vote his shares in favor of the Proposal to remove lock-up restrictions at the 2025 Annual Meeting.
• Dr. Joseph Lawler to vote his shares in favor of Aron English's election to the board at subsequent meetings.

Key Dates

Recommendation

Keywords

Anebulo Pharmaceuticals, SEC filing, Schedule 13D, beneficial ownership, private placement, lock-up agreement, support agreement, corporate governance, shareholder vote, director election, 22NW Fund, Pharma Investors, Aron English, Joseph Lawler